Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Shareholder Meeting (November 2018)
11 slides from Bio-gene Technology's shareholder meeting presentation, Nov 20, 2018
Slide 1: AGM Presentation November 2018
For personal use only (ASX:BGT) AGM Presentation November 2018
Slide 2: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Bio-Gene Technologies Limited (referred to as “Bio-Gene”, “BGT” or the “Company”). The information in this Document is not intended to form the basis of any investment decision in relation t
Slide 3: The Global Problem of Pest Control
The Global Problem of Pest Control For personal use only The Ag-Chem industry is seeking new & safer Pest Environmental chemistry as global resistance Resistance Impact continues to worsen Pests are rapidly Public outrage at incumbent developing resistance to products’ toxic impact on bees current i
Slide 4: In recent years the problem has worsened
In recent years the problem has worsened For personal use only Increasing number of resistant species New insecticides are increasingly elusive 700 160,000 Species Resistant Molecules Screened 586 insect species now >140,000 molecules must 600 resistant to at least one 140,000 be screened to discove
Slide 5: New compounds must demonstrate multiple qualities
New compounds must demonstrate multiple qualities For personal use only Safe Novel Mode Efficacy Scalability Chemistry of Action Compound must New ‘soft chemistries‘ Compounds must Technology must be effective, are required, have a novel Mode be able to be either alone or which don’t of Action (MoA)
Slide 6: Bio-Gene's technology addresses these needs
Bio-Gene’s technology addresses these needs For personal use only Safe Novel Mode Efficacy Scalability Chemistry of Action Data shows Flavocide™ Trials show relatively Bio-Gene’s compounds CSIRO collaboration & Qcide™ are highly low toxicity to operate via a has refined effective for controlling bee
Slide 7: Bio-Gene has two unique compounds
Bio-Gene has two unique compounds For personal use only Qcide™ Flavocide™ Natural Compound Nature Identical Compound Extract of an A chemical process is Australian eucalypt: used to produce a ‘Gypmie Messmate’ ‘synthetic copy’ of the compound that can be Qcide™ is well suited mass produced to applic
Slide 8: Well-defined pathway to commercialisation
Well-defined pathway to commercialisation For personal use only Testing & Data Generation Well Create suite of trial data & IP relating to efficacy, toxicity, mode of action and manufacturing Progressed Introductory Commercial Discussions Globally Present Bio-Gene to major Ag-Chem, Government Agenci
Slide 9: Bio-Gene has delivered on multiple milestones in 2018
Bio-Gene has delivered on multiple milestones in 2018 For personal use only Significant Suite of Trial Data Toxicology Studies to Multiple Partnership for Proof of Concept Support Registration Discussions Efficacy Testing Expanded Knowledge Strengthened Improved Appointed Expert of Mode of Action In
Slide 10: Financial Overview
Financial Overview For personal use only 0.3 2 Volume (m) Strong Cash Position BGT has a well funded balance sheet 0.2 with ~$6m in cash (as at end September 1 18), providing a ~2 year runway 0.1 Capital Structure & Financials 0 0 Shares on Issue 128m Nov-17 Feb-18 May-18 Aug-18 Nov-18 Volume Share
Slide 11: Bio-Gene Technology Ltd
For personal use only BIO-GENE TECHNOLOGY LTD
Bio-Gene Technology — Shareholder Meeting (November 2018) on 6ix